Can a Psychedelic From Toad Venom Help When Antidepressants Fail?
A study published in JAMA found that 5-MeO-DMT, a psychedelic from toad venom, significantly reduced symptoms in treatment-resistant depression patients. Administered as a nasal spray, the drug showed remission rates of 18-26% after a month. The study was funded by AtaiBeckley, recently acquired by Eli Lilly, which plans further evaluation. Side effects were mostly mild, with headaches and nausea being common.
How this was made
The 30-second read
Why it matters
The trial shows remission rates of 18‑26% versus 8% placebo, suggesting a potentially valuable new therapy for a large unmet need.
Market read
First disclosure of promising Phase 2b data could influence biotech sentiment and Eli Lilly's valuation.
What to watch
Regulatory hurdles and commercialization timeline could delay any material benefit.
Background
The article reports first‑time Phase 2b results for intranasal 5‑MeO‑DMT (mebufotenin) in treatment‑resistant depression, funded by AtaiBeckley, now owned by Eli Lilly.
Ticker impact
Eli Lilly acquired AtaiBeckley, the funder of the Phase 2b 5-MeO-DMT trial, linking the company to potential new antidepressant pipeline.
likely upward pressure as investors price in a new asset opportunity.
Phase 2b results are encouraging but early; market may react cautiously.
Market effects
could spark broader interest in psychedelic therapeutics within pharma.
U.S. biotech sector may see modest gains.
global investors watch mental‑health pipeline developments.
Counterpoint
Skeptics may view the data as preliminary and discount any near‑term impact on Eli Lilly.
Key entities
- CompanyEli Lilly
Pharmaceutical giant that acquired AtaiBeckley, linking it to the trial.
- CompanyAtaiBeckley
Biotech funder of the trial, now part of Eli Lilly.
